Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Braveheart Bio (BRVE) looks undervalued in late-stage HCM with funded Phase 3 trials, strong cash runway and nHCM upside.

Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A ...

SHANGHAI and SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated All share and per share amounts for all periods presented have been retroactively adjusted to give ...